Study of Ozanimod's Effects on Immune Cells in Ulcerative Colitis
Part of Digestive system clinical trials.
This study looks at how the medicine ozanimod works in people with active ulcerative colitis. Researchers will use a special blood test to understand how the drug affects your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with ulcerative colitis for at least 3 months, confirmed by a colonoscopy and biopsy.
- A recent colonoscopy shows your UC is active.
- You are planning to start ozanimod (a pill) and not using it with another biologic drug.
- You are not at high risk for needing colon surgery soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This study is checking the safety of ozanimod, a daily pill, for people with moderate to severe active ulcerative colitis. It looks at how well patients tolerate the medicine in real-world use in Korea.
This trial studies how ozanimod affects pregnant people with ulcerative colitis and their babies. It may help doctors understand safety and outcomes when this medicine is used during pregnancy and after birth.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.